Focused on developing treatments for retinal degenerative diseases, the company is a clinical‑stage biopharmaceutical developer advancing small‑molecule therapies that target vitamin A transport pathways. Its lead candidate, tinlarebant, is being studied for conditions such as Stargardt disease and ...
This page tracks all publicly disclosed congressional trades in Belite Bio, Inc (BLTE), a company in the Healthcare sector. All data is sourced from STOCK Act Periodic Transaction Reports filed with the House and Senate disclosure offices.
No congressional trades found for this stock.